AN2 Therapeutics, Inc.
NASDAQ:ANTXBiotechnology
+$0.04 today
- Market cap
- $187.82M
- Beta
- -0.98
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$1.01
Volume 0.97M
Average 0.29M
ANTX Account Payables
Amounts the company owes suppliers for goods and services received.
AN2 Therapeutics, Inc.NASDAQ: ANTX
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 14.9% from a year ago
Account payables stood at $2.62M at the end of Q1 FY2026, down 14.9% from a year earlier and down 13.4% from the prior quarter. Over 3 fiscal years it compounded at +12.5% a year.
Context
- Account payables amounted to 3.0% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -14.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 3.02M USD
- Year-over-year change
- -8.9%
- 4-year CAGR
- +29.8%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.02M | -8.9% |
| FY2024 | 2024-12-31 | 3.32M | +24.0% |
| FY2023 | 2023-12-31 | 2.68M | +26.1% |
| FY2022 | 2022-12-31 | 2.12M | +99.6% |
| FY2021 | 2021-12-31 | 1.06M | — |
Account Payables vs competitors
How ANTX compares with its peers on the latest reported figures
- ANTX's Mar 2026 account payables of $2.62M is the 3rd highest of the 6 companies compared; the peer median is $2.19M.
- Its year-over-year change of -14.9% is the 5th highest of 6, against a peer median of +49.0%.
- Account payables amounts to 3.0% of total assets for ANTX, versus a peer median of 1.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $4.42M | +102.1% | +33.7% | 4.5% | |
| Jun 2026 | $3.86M | +47.0% | -5.1% | 1.6% | |
| Mar 2026 | $2.62M | -14.9% | +12.5% | 3.0% | |
| Mar 2026 | $2.19M | +52.0% | +59.9% | 5.7% | |
| Mar 2026 | $2.04M | +49.0% | +2.1% | 1.4% | |
| Mar 2026 | $653K | -75.9% | -15.1% | 1.0% | |
| Peer median (excluding ANTX) | $2.19M | +49.0% | +2.1% | 1.6% | |
Competitors are the stored peer set for ANTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 12.1M | 27.22M | 15.65M | 21.35M | 19.94M |
| Short-term Investments | 46.46M | 68.84M | 91.65M | 62.27M | 38.06M |
| Net Receivables | 0 | 0 | 1.4M | 300K | 900K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 1.55M | 2.56M | 3.21M | 2.34M | 1.04M |
| Total Current Assets | 60.11M | 98.62M | 110.51M | 86.26M | 59.94M |
| Property, Plant & Equipment (Net) | 0 | 53K | 0 | 0 | 0 |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 3.49M | 3.22M | 27.19M | 5.02M | 2.01M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.72M | 667K | 1.04M | 804K | 0 |
| Total Non-current Assets | 5.21M | 3.94M | 28.24M | 5.83M | 2.01M |
| Total Assets | 65.32M | 102.56M | 138.74M | 92.09M | 61.95M |
| Account Payables | 1.06M | 2.12M | 2.68M | 3.32M | 3.02M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 330K | 6K | 4.69M | 2.47M | 3.28M |
| Total Current Liabilities | 3.4M | 7.19M | 14.04M | 10.24M | 8.72M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13K | 2K | 0 | 0 | 170K |
| Total Non-current Liabilities | 13K | 2K | 0 | 0 | 170K |
| Total Liabilities | 3.41M | 7.19M | 14.04M | 10.24M | 8.89M |
| Common Stock | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | (47.38M) | (89.72M) | (154.46M) | (205.78M) | (240.95M) |
| Accumulated OCI | (27K) | (374K) | 275K | 31K | 57K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 61.91M | 95.37M | 124.7M | 81.85M | 53.06M |
| Total Debt | 0 | 53K | 0 | 0 | 0 |
| Net Debt | (12.1M) | (27.17M) | (15.65M) | (21.35M) | (19.94M) |
AN2 Therapeutics, Inc.
NASDAQ:ANTX
Intrinsic Alpha fair value
Locked
Current Price
$4.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.